Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Indenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 10/20 | 0.57 |
| ▸ | ADRB1 known ✓ | P08588 | 10/20 | 0.57 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.57 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.57 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.57 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.55 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.55 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.55 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.55 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.55 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.55 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.55 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indenolol SCHEMBL349114 | 1.00 | ADRB2 (0.57) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Indenolol SCHEMBL79023 | 0.99 | ADRB2 (0.56) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Indenolol SCHEMBL79021 | 0.99 | ADRB2 (0.56) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Indenolol SCHEMBL1650473 | 0.96 | ADRB2 (0.54) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| SCHEMBL11631654 | 0.91 | ADRB2 (0.47) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| SCHEMBL11656702 | 0.88 | ADRB2 (0.44) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Idropranolol SCHEMBL1255318 | 0.87 | ADRB1 (0.54) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL11659927 | 0.86 | ADRB2 (0.46) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| Indenolol SCHEMBL11666579 | 0.85 | ADRB2 (0.48) | ADRB2ADRB1ADRB3SIGMAR1HTR2A | |
| SCHEMBL11754160 | 0.84 | ALOX15 (0.41) | ADRB2ADRB1ADRB3SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-20100099639-A1 | W/O/W EMULSION COMPOSITION | CONTROLLED LIPO TECHS, INC. (JP) | 2010-04-22 | — | — | US | claimed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | claimed |
| EP-2077106-A1 | W/O/W EMULSION COMPOSITION | Controlled Lipo Techs, Inc. (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | claimed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20040022848-A1 | Medicinal composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1319399-A1 | MEDICINAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| EP-0974361-A1 | METHOD OF USING ANTACID AGENT AND PHARMACEUTICAL PREPARATION CONTAINING ANTACID AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-01-26 | — | — | EP | claimed |
| US-5985843-A | PHARMACEUTICAL PREPARATION THAT CONTAINS SUCRALFATE IN THE PRESENCE OF ANOTHER DRUG IN SUCH A WAY THAT THE ANOTHER DRUG IS IMMEDIATELY RELEASED WITHOUT BEING ADSORBED ON OR TRAPPED BY THE SUCRALFATE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-11-16 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0823255-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SUCRALFATE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-02-11 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099639-A1 | W/O/W EMULSION COMPOSITION | PLA2G2C, OSTC, LIPA | ADRB2 495/4885ADRB1 515/4885ADRB3 591/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | ADRB2 430/4885ADRB1 230/4885ADRB3 252/4885 |
| US-20040022848-A1 | Medicinal composition | CD44, CMA1, ACLY | ADRB2 2497/4885ADRB1 2249/4885ADRB3 2250/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | ADRB2 1447/4885ADRB1 693/4885ADRB3 888/4885 |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | CMA1, HRH2, ACLY | ADRB2 2646/4885ADRB1 2424/4885ADRB3 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.